Logo image of ALTHX.PA

THERANEXUS SADIR (ALTHX.PA) Stock Fundamental Analysis

EPA:ALTHX - Euronext Paris - Matif - FR0013286259 - Common Stock - Currency: EUR

1.015  +0.01 (+1.5%)

Fundamental Rating

1

Overall ALTHX gets a fundamental rating of 1 out of 10. We evaluated ALTHX against 53 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ALTHX have multiple concerns. ALTHX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALTHX has reported negative net income.
In the past year ALTHX has reported a negative cash flow from operations.
ALTHX had negative earnings in each of the past 5 years.
In the past 5 years ALTHX always reported negative operating cash flow.
ALTHX.PA Yearly Net Income VS EBIT VS OCF VS FCFALTHX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

ALTHX has a worse Return On Assets (-72.26%) than 84.91% of its industry peers.
Industry RankSector Rank
ROA -72.26%
ROE N/A
ROIC N/A
ROA(3y)-65.69%
ROA(5y)-52.17%
ROE(3y)-167.24%
ROE(5y)-120.86%
ROIC(3y)N/A
ROIC(5y)N/A
ALTHX.PA Yearly ROA, ROE, ROICALTHX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALTHX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALTHX.PA Yearly Profit, Operating, Gross MarginsALTHX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for ALTHX has been increased compared to 1 year ago.
Compared to 5 years ago, ALTHX has more shares outstanding
ALTHX has a worse debt/assets ratio than last year.
ALTHX.PA Yearly Shares OutstandingALTHX.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALTHX.PA Yearly Total Debt VS Total AssetsALTHX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -2.40, we must say that ALTHX is in the distress zone and has some risk of bankruptcy.
ALTHX's Altman-Z score of -2.40 is on the low side compared to the rest of the industry. ALTHX is outperformed by 79.25% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.4
ROIC/WACCN/A
WACCN/A
ALTHX.PA Yearly LT Debt VS Equity VS FCFALTHX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

ALTHX has a Current Ratio of 2.31. This indicates that ALTHX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ALTHX (2.31) is better than 81.13% of its industry peers.
A Quick Ratio of 2.31 indicates that ALTHX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 2.31, ALTHX belongs to the best of the industry, outperforming 90.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.31
Quick Ratio 2.31
ALTHX.PA Yearly Current Assets VS Current LiabilitesALTHX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.48% over the past year.
EPS 1Y (TTM)68.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 30.26% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y88%
EPS Next 2Y40.36%
EPS Next 3Y30.26%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALTHX.PA Yearly Revenue VS EstimatesALTHX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2018 2021 5M 10M 15M
ALTHX.PA Yearly EPS VS EstimatesALTHX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALTHX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALTHX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALTHX.PA Price Earnings VS Forward Price EarningsALTHX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALTHX.PA Per share dataALTHX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as ALTHX's earnings are expected to grow with 30.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.36%
EPS Next 3Y30.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALTHX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERANEXUS SADIR

EPA:ALTHX (6/2/2025, 7:00:00 PM)

1.015

+0.01 (+1.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-29 2025-04-29/amc
Earnings (Next)09-25 2025-09-25
Inst Owners9.44%
Inst Owner ChangeN/A
Ins Owners9.44%
Ins Owner ChangeN/A
Market Cap7.88M
Analysts86.67
Price Target5 (392.61%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-20.97%
PT rev (3m)-20.97%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)88.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0
BVpS0
TBVpS-0.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.26%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.69%
ROA(5y)-52.17%
ROE(3y)-167.24%
ROE(5y)-120.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.38%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.31
Quick Ratio 2.31
Altman-Z -2.4
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)17.36%
Cap/Depr(5y)297.4%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.91%
EPS Next Y88%
EPS Next 2Y40.36%
EPS Next 3Y30.26%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y43.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.29%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.07%
OCF growth 3YN/A
OCF growth 5YN/A